Skip to main content

Mª Ángeles Muchada López

Institutions of which they are part

Main researcher
Stroke research
Vall Hebron Institut de Recerca

Mª Ángeles Muchada López

Institutions of which they are part

Main researcher
Stroke research
Vall Hebron Institut de Recerca

Projects

NexTOLL: A Phase IIb Clinical Trial to evaluate the neuroprotective effect of ApTOLL in stroke patients

IP: Marc Ribó Jacobi
Collaborators: Marta Aurora Rubiera Del Fueyo, Jorge Pagola Pérez Blanca, Carlos Molina Cateriano, Mª Ángeles Muchada López
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 498435
Reference: CPP2022- 009778
Duration: 09/03/2023 - 08/03/2026

Ministerio de Ciencia

Optimització del tractament endovascular a l'ictus isquèmic agut

IP: Mª Ángeles Muchada López
Collaborators: Marc Rodrigo Gisbert, Laia Perez Lasarte
Funding agency: Fundació Institut de Recerca HUVH
Funding: 35000
Reference: CARLESM/MARC_RG
Duration: 08/06/2023 - 07/06/2024

NORA-HOME. EFICIENCIA Y SEGURIDAD DE UN MODELO DE MONITORIZACION MULTIMODAL AMBULATORIA EN PACIENTES CON ICTUS MINOR Y AITS.

IP: Mª Ángeles Muchada López
Collaborators: Carlos Molina Cateriano, Alvaro Garcia Tornel Garcia Camba, Marc Rodrigo Gisbert
Funding agency: Instituto de Salud Carlos III
Funding: 123420
Reference: PI22/01928
Duration: 01/01/2023 - 31/12/2025

Impact of time to achieve blood pressure control on hematoma expansion in patients with acute intracerebral hemorrhage

IP: David Rodriguez Luna
Collaborators: Maria Mar Hernandez Guillamon, Mª Ángeles Muchada López
Funding agency: Fundació La Marató de TV3
Funding: 177052.88
Reference: 20173030
Duration: 01/01/2018 - 31/01/2022

Related news

UMBRELLA, a consortium of over 20 public and private partners, kicks off this week with the aim of revolutionising the entire stroke care pathway in Europe by adopting a holistic approach that covers stroke diagnosis, prevention and care.

The Consortium will create a platform to facilitate a personalised management for stroke patients, enabling a more efficient personalized monitoring and patient follow up.

Funding is key to bringing the neuroprotective drug ApTOLL to market and providing a new therapeutic option for the patients.

Related professionals

Laia Josa Culleré

Laia Josa Culleré

Postdoctoral researcher
Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more
Joana Ramis Garcia

Joana Ramis Garcia

Predoctoral researcher
Pharmacokinetic Nanoparticles
Read more
Alena Gros Vidal

Alena Gros Vidal

Main researcher
Read more
Mario Marotta Baleriola

Mario Marotta Baleriola

Main researcher
Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.